Pfizer Inc

PFE

Equity

ISIN null / Valor 962004

New York Stock Exchange, Inc (2026-08-26)

USD 28.30-0.95%

Pfizer Inc
UMushroom community rating:

3.83 12 votes No rating yet

NegativeNeutralPositive

About company

Pfizer Inc. is a global pharmaceutical corporation that engages in the discovery, development, manufacture, and marketing of a wide range of healthcare products. Its operations span across various segments including innovative health and established health products, focusing on areas such as internal medicine, vaccines, oncology, inflammation and immunology, and rare diseases. Pfizer is known for its commitment to research and development, aiming to address unmet medical needs and improve patient outcomes. The company has made significant strides in the pharmaceutical industry by launching initiatives like an online site for up-to-date information on its U.S. post-marketing commitments, which underscores its dedication to transparency and safety in medicine. Additionally, Pfizer has expanded its reach into animal health through its Agricultural Division, and has ventured into regenerative medicine with the establishment of its Global Regenerative Medicine Unit. The acquisition of Mack Illertissen and the strategic integration of Hospira's portfolio of biosimilars highlight Pfizer's efforts to broaden its product offerings and strengthen its position in the global market. By segmenting its commercial operations into innovative and value business lines, Pfizer aims to cater to both developed and emerging markets, leveraging its scientific expertise and global scale to meet diverse healthcare needs.

Summarized from source with an LLMView SourceSector: Healthcare

Alexander Schröder

Switzerland, 19 Mar 2026

Post-COVID revenue normalization pressures growth, with declining vaccine sales weighing on performance. Pipeline and oncology acquisitions provide optionality, but near-term catalysts remain limited.

Matthew Tombaugh

Switzerland, 16 Mar 2026

Transitioning effectively from COVID peak to a catalyst-rich pipeline. The Metsera acquisition and GLP-1 data position PFE as a serious contender in the $150B obesity market.

Emily Quinapanta

UK, 07 Nov 2025

Pfizer is undergoing increasing pressures in revenues after the global health pandemic however it’s focused in public healthcare is a necessity which brings forward long term growth posssibikities . Still remains world leader for R&D hence is a stable company just hasn’t seen increasing revenues .

EQUITIES OF THE SAME SECTOR

Boiron SA